Is BridgeBio Oncology Therapeutics Inc. (BBOT) a Buy, Sell, or Hold?
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$8.41 USD
-$0.41 (-4.65%)
- Volume
- 457.22K
- Average Volume
- 472.3K
- Market Capitalization
- $673.7M
- P/E Ratio
- -1.47
- Dividend Yield
- 0.00%
- Price Target
- $23.00
- Year High
- $14.87
- Year Low
- $7.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.16
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Pedro J. Beltran |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BBOT |
| CUSIP | 107924102 |
| CIK | 0001869105 |
| Web | https://bbotx.com |
| Phone | 650 405 4770 |
| Currency | USD |
| Employees | 92 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.16 |
| Quick Ratio | 6.16 |
| Cash Ratio | 1.22 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -5.55 |
| Price / Cash Flow | -3.90 |
| Price / Book | 0.70 |
Price Target and Rating
| Average Stock Price Forecast | $23.00 |
| High Stock Price Forecast | $23.00 |
| Low Stock Price Forecast | $23.00 |
| Forecast Upside/Downside | -63.43% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-4.3 |
| Trailing P/E Ratio | -1.47 |
| PEG Ratio | 0.02 |
| P/E Growth | 0.02 |
| Net Income | $-134.04M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -61.49% |
| Return on Assets | -36.90% |
Financials Score
| AltmanZ Score | 7.00 |
| Piotroski Score | 1.00 |
| Working Capital | 223.24M |
| Total Assets | 417.65M |
| Ebit | -168.86M |
| Market Cap | 682.51M |
| Total Liabilities | 45.37M |
Poll Results
About BridgeBio Oncology Therapeutics Inc. (NASDAQ:BBOT) Stock
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initi ... atives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment
2026-07-13 11:20:58
BridgeBio Oncology Therapeutics remains a Buy, despite a >30% decline since prior coverage, supported by three promising KRAS/RAS-targeted drug candidates. BBOT's lead asset, BB-8520, showed a 65% objective response rate and 100% disease control in KRAS G12C NSCLC, exceeding results from approved competitors. Further mature data readouts for BBOT's pipeline are expected in 2H26, representing key catalysts for share price re-rating and future funding opportunities.
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
2026-05-12 17:03:00
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress.
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-05-12 16:05:00
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on May 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in March 2026.
2026-05-11 07:58:15
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as reports indicate that President Trump declined Iran's counteroffer for peace. This comes after a remarkable Friday, when stocks roared to record highs, driven primarily by a stronger-than-expected April jobs report that eased economic concerns and by a... Here Are Monday's Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy's, and More
2026-04-22 16:05:00
BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines
2026-04-22 09:00:00
Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development experience and scientific/business acumen to bear as the company's top executive Idan Elmelech, who previously served as Senior Vice President of Strategy & Business Development, will assume the position of Chief Operating Officer overseeing finance & accounting, corporate strategy, operations, and business development Neil Kumar, PhD, who played an integral role in the founding of BBOT as part of BridgeBio Pharma, Inc., has been appointed as Executive Chairman by the Board of Directors to guide the company as it embarks on its next stage of development Former CEO, Eli Wallace, PhD, will serve as a Senior Adviser to the company, continuing to leverage his scientific expertise and deep understanding of BBOT's programs to support the company going forward SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced the appointment of Pedro J.
2026-04-21 17:30:00
BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycemia
BridgeBio Oncology Therapeutics: Poised To Bank On The KRAS Revolution
2026-04-21 11:39:50
BridgeBio Oncology Therapeutics is advancing differentiated KRAS inhibitors, targeting both active and inactive KRAS conformations in solid tumors, notably pancreatic cancer. BridgeBio Oncology's lead candidate BBO-11818 and G12C-specific BBO-8520 both hold FDA Fast Track designation, with early data showing promising tolerability and response rates. Strong cash position ($373.7M at 2025 year-end) provides a runway into 2028, supporting clinical milestones and mitigating near-term funding risk.
Frequently Asked Questions
-
What is the current BridgeBio Oncology Therapeutics Inc. (BBOT) stock price?
-
BridgeBio Oncology Therapeutics Inc.(NASDAQ:BBOT) stock price is $8.41 in the last trading session. During the trading session, BBOT stock reached the peak price of $14.87 while $7 was the lowest point it dropped to. The percentage change in BBOT stock occurred in the recent session was --4.65% while the dollar amount for the price change in BBOT stock was -$-0.41.
-
BBOT's industry and sector of operation?
-
The NASDAQ listed BBOT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BBOT?
-
Rui Xu | Senior Vice President of Drug Discovery
Aaron Chan | Vice President of Legal
Daniel Watson | Senior Vice President of Chemistry, Manufacturing & Controls
Idan Elmelech | Chief Operating Officer
Bin Wang | Senior Vice President of Drug Discovery -
How many employees does BBOT have?
-
Number of BBOT employees currently stands at 92. BBOT operates from 256 E. Grand Avenue, South San Francisco, CA 94080, US.
-
Link for BBOT official website?
-
Official Website of BBOT is: https://bbotx.com
-
How do I contact BBOT?
-
BBOT could be contacted at phone #650 405 4770 and can also be accessed through its website. BBOT operates from 256 E. Grand Avenue, South San Francisco, CA 94080, US.
-
How many shares of BBOT are traded daily?
-
The average number of BBOT shares traded daily for last 3 months was 472.3K.
-
What is the market cap of BBOT currently?
-
The market value of BBOT currently stands at $673.7M with its latest stock price at $8.41